DAWN
Day One Biopharmaceuticals Inc
NASDAQ: DAWN · HEALTHCARE · BIOTECHNOLOGY
$21.53
+0.00% today
Updated 2026-04-23
Market cap
$2.22B
P/E ratio
—
P/S ratio
14.06x
EPS (TTM)
$-1.04
Dividend yield
—
52W range
$6 – $22
Volume
4.5M
Day One Biopharmaceuticals Inc (DAWN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $131.16M | $158.18M |
| Revenue growth (YoY) | — | — | — | — | — | — | +20.6% |
| Cost of revenue | — | $155000.00 | $199000.00 | $531000.00 | $383000.00 | $5.28M | $17.21M |
| Gross profit | — | $-155000.00 | $-199000.00 | $-531000.00 | $-383000.00 | $125.88M | $140.97M |
| Gross margin | — | — | — | — | — | 96.0% | 89.1% |
| R&D | $13.90M | $9.10M | $43.58M | $85.62M | $130.52M | $227.70M | $148.13M |
| SG&A | $1.01M | $4.68M | $29.16M | $61.29M | $75.54M | $31.55M | $120.59M |
| Operating income | $-14.90M | $-13.78M | $-72.74M | $-146.91M | $-206.06M | $-217.27M | $-127.75M |
| Operating margin | — | — | — | — | — | -165.7% | -80.8% |
| EBITDA | $-2000.00 | $-43.66M | $-72.54M | $-146.38M | $-188.53M | $-86.32M | $-105.82M |
| EBITDA margin | — | — | — | — | — | -65.8% | -66.9% |
| EBIT | $-14.91M | $-43.81M | $-72.74M | $-146.91M | $-188.92M | $-88.35M | $-109.30M |
| Interest expense | $2.08M | $30000.00 | $4000.00 | $4.75M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-12.63M | $-40.51M | $-70.44M | $-132.18M | $-188.92M | $-95.50M | $-107.32M |
| Net income growth (YoY) | — | -220.6% | -73.9% | -87.6% | -42.9% | +49.5% | -12.4% |
| Profit margin | — | — | — | — | — | -72.8% | -67.8% |